Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × Idarubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 24 Leukemia 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Leukemia, Myelomonocytic, Acute 6 Leukemia, Monocytic, Acute 6 Leukemia, Megakaryoblastic, Acute 6 Leukemia, Erythroblastic, Acute 6 Myelodysplastic Syndromes 4 Leukemia, Promyelocytic, Acute 4 Anemia, Refractory, with Excess of Blasts 4 Neoplasms, Plasma Cell 3 Multiple Myeloma 3 Leukemia, Myelomonocytic, Chronic 3 Leukemia, Myeloid, Chronic-Phase 3 Neutropenia 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Congenital Abnormalities 2 Anemia, Refractory 2 Sarcoma, Synovial 1 Sarcoma 1 Rhabdomyosarcoma 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Lymphoma, Mantle-Cell 1

Interventions

Doxorubicin 22 Ifosfamide 19 Radiotherapy 14 Vincristine 9 Etoposide 9 Filgrastim 8 Cyclophosphamide 8 Trabectedin 7 Dactinomycin 7 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Chemotherapy, Adjuvant 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Docetaxel 2 Dexrazoxane 2 Dacarbazine 2 trofosfamide 1 trioctyl phosphine oxide 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00876031 2022-11-08

CWS-2007-HR

University Hospital Tuebingen

Phase 3 Completed

Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡